O17-2 Tafasitamab + lenalidomide versus lenalidomide monotherapy in transplant-ineligible patients with R/R DLBCL (RE-MIND)
Grzegorz S. Nowakowski,Thomas D. Rodgers,Dario Marino,Maurizio Frezzato,Anna Maria Barbui,Claudia Castellino,Erika Meli,Nathan Fowler,Bruce Feinberg,Sascha Tillmanns,Stephan Parche,Günter Fingerle-Rowson,Mark Winderlich,Sumeet Ambarkhane,Gilles Salles,Pier Luigi Zinzani ANNALS OF ONCOLOGY（2021）
AI 理解论文
溯源树
样例
